The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery (RAPID)

June 14, 2023 updated by: Christian Reiterer, Medical University of Vienna

The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery in Patients Undergoing Minor- to Moderate-risk Noncardiac Surgery - a Prospective Double-blinded Randomized Clinical Trial

Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching a modified Aldrete score ≥ 12, as compared to sevoflurane in patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery.

Study Overview

Detailed Description

Background: Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching amodified Aldrete score ≥ 12, as compared to sevoflurane in patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery.

Methods: The investigators will include 190 patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery in this randomized, double-blinded clinical trial. Patients will be randomly assigned to receive desflurane or sevoflurane throughout surgery for maintenance of anesthesia. The primary outcome will be the time between discontinuation of desflurane until full postoperative recovery assessed via consecutive Aldrete Score assessments in the first 90 minutes after arrival at PACU. Aldrete Score will be assessed upon arrival at PACU and thereafter in five-minute intervals.

Statistics: The primary outcome, the time from discontinuation of volatile anesthetic agent to reaching discharge criteria from PACU assessed via Aldrete Score values,will be compared between both study groups using a Mann-Whitney-U test. Furthermore, the investigators will perform a median regression model for time to Aldrete score ≥ 12 points accounting for group as a factor as well as further covariables e.g. age, gender, weight.

Level of originality: Data regarding the effects of general anesthesia using desflurane in comparison to sevoflurane on postoperative recovery are mainly available from small studies. So far, there is very limited data on postoperative recovery and neurocognitive rehabilitation in elderly patients. However, this patient population is at a higher risk of developing postoperative neurocognitive complications, and could therefore, profit from a more rapid resurgence from anesthesia and postoperative recovery. Moreover, outpatient surgery will be becoming even more important. Therefore, reduction in postoperative PACU stay in combination with a decreased risk to develop postoperative delirium or cognitive dysfunction, might therefore improve outcome in this patient population as well.

Study Type

Interventional

Enrollment (Actual)

190

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Vienna, Austria, 1100
        • Medical University of Vienna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 95 years (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ≥ 65 years of age at time of surgery
  • Scheduled for elective minor- to moderate-risk noncardiac surgery with expected time of surgery ≤ 2 hours

Exclusion Criteria:

  • Patients undergoing emergency surgery
  • Patients undergoing bariatric surgery
  • History of documented dementia / neurologic disorder
  • Language, vision, or hearing impairments that may compromise cognitive assessments
  • History of malignant hyperthermia
  • History of structural muscle disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Desflurane Group
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
Active Comparator: Sevoflurane Group
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Aldrete Score
Time Frame: Consecutive measurements until reaching 12 points for a maximum of 90 minutes after surgery and reaching PACU.
A score to assess readiness of discharge from postanesthesia care unit (PACU). Patients can achieve 0-14 points in the modified Aldrete Score. A modified Aldrete Score > 12 points signals that criteria for discharge from PACU have been fulfilled, a modified Aldrete Score < 12 points signals that patients should stay in PACU.
Consecutive measurements until reaching 12 points for a maximum of 90 minutes after surgery and reaching PACU.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary Outcome 1: Number of liters of supplemental oxygen administered in PACU for SpO2 ≥ 93%
Time Frame: Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Postoperative need for administration of supplemental oxygen to maintain a SpO2 of ≥ 93% during PACU stay
Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Secondary Outcome 2: Postoperative cerebral oxygen saturation
Time Frame: Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Postoperative non-invasive near-infrared spectroscopy for measurement of cerebral oxygenation
Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Secondary Outcome 3: Postoperative bispectral index values
Time Frame: Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Postoperative continuous measurement of bispectral index for detection of postoperative aftereffects of anesthesia on awareness
Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.
Secondary Outcome 4: Ready for Hospital Discharge Scale Scores
Time Frame: For the first three postoperative days
A score to evaluate patients' subjective readiness for hospital discharge. Patients can achieve 0-80 points in the Ready for Hospital Discharge Scale. Higher scores mean that patients are ready for hospital discharge, lower scores mean that patients are not ready for hospital discharge.
For the first three postoperative days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tertiary Outcome 1: NT-proBNP
Time Frame: Within the first two postoperative days
Maximum concentrations of NT-proBNP
Within the first two postoperative days
Tertiary Outcome 2: Troponin T
Time Frame: Within the first two postoperative days
Maximum concentrations of Troponin T
Within the first two postoperative days
Tertiary Outcome 3: Copeptin
Time Frame: Within the first two postoperative days
Maximum concentrations of Copeptin
Within the first two postoperative days
Tertiary Outcome 4: Interleukin-6
Time Frame: Within the first two postoperative days
Maximum concentrations of Interleukin-6
Within the first two postoperative days
Tertiary Outcome 5: Procalcitonin
Time Frame: Within the first two postoperative days
Maximum concentrations of Procalcitonin
Within the first two postoperative days
Tertiary Outcome 6: CRP
Time Frame: Within the first two postoperative days
Maximum concentrations of CRP
Within the first two postoperative days
Tertiary Outcome 7: S100-B
Time Frame: Within the first two postoperative days
Maximum concentration of S-100B
Within the first two postoperative days
Exploratory Outcome 8: Delirium
Time Frame: For the first three postoperative days
3D-CAM questionnaires for the evaluation of postoperative delirium. Patients can achieve 0-22 points in the 3D-CAM questionnaire. Higher scores indicate confusion, lower scores indicate no confusion.
For the first three postoperative days
Exploratory Outcome 9: Postoperative cognitive dysfunction
Time Frame: 30 days after surgery
Montreal cognitive assessments for the evaluation of long-term postoperative cognitive dysfunction. Patients can achieve 0-22 points in the Montreal cognitive assessment. A reduction of 2 points from baseline indicates postoperative cognitive dysfunction.
30 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christian Reiterer, MD, Medical University of Vienna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

June 1, 2023

Study Completion (Actual)

June 1, 2023

Study Registration Dates

First Submitted

April 8, 2022

First Submitted That Met QC Criteria

April 8, 2022

First Posted (Actual)

April 15, 2022

Study Record Updates

Last Update Posted (Actual)

June 15, 2023

Last Update Submitted That Met QC Criteria

June 14, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We will not share any individual participant data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Delirium

Clinical Trials on Desflurane

Subscribe